

09/869894
JC18 Rec'd PCT/PTO 06 JUL 2001
5-2802
attachment

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0573
Inventors: Ackermann et al.
Serial No.: Not Yet Assigned
Filing Date: Herewith
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Antisense Modulation of Novel Anti-Apoptotic BCL-2-Related Proteins

"Express Mail" Label No. EL780366205US
Date of Deposit July 6, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)


are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: July 6, 2001

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

09/869894

JC18 Rec'd PCT/PTO 0 6 JUL 2001

Sheet 01 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0573	Serial No. Not Yet Assigned
	Applicant Ackermann et al.	
	Filing Date Herewith	Group Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	AA	5,583,034	12-10-96	Green et al.	435	240.2

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AB	WO 96/30513	10-3-96	PCT	x	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified		Docket No. ISPH-0573	Serial No. Not Yet Assigned
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Ackermann et al.	
U.S. Department of Commerce		Filing Date Herewith	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Crooke S.T., "Basic Principles of Antisense Therapeutics", <i>In:Antisense Research And Applications, Chapter 1, Springer-Verlag Press, Berlin, Heidelber, New York 1998</i>	
	AB	Chao et al., "mcl-1 Is an Immediate-Early Gene Activated by the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Signaling Pathway and Is One Component of the GM-CSF Viability Response", <i>Molecular and Cellular Biology</i> 1998 4883-4898	
EXAMINER		DATE CONSIDERED	